Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients With Gynecological Cancer After Undergoing Surgery

Female Reproductive Cancer Clinical Trial

Official title:

MC1267, A Randomized, Blinded Pilot Placebo-Controlled Trial With Oral Serum Bovine Immunoglobulin (SBI) to Assess Quality of Life and the Faster Post-Operative Recovery of Gynecological Cancer Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01867606
• Other study ID #: MC1267
• Secondary ID: NCI-2013-00866MC
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 4, 2013
• Est. completion date: October 2024

Study information

• Verified date: May 2024
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized pilot phase II trial studies how well serum bovine immunoglobulin protein isolate works in improving quality of life and post-operative recovery in patients with cancer of the female reproductive tract after undergoing surgery. Serum bovine immunoglobulin may help provide nutrition to patients who are not able to eat or digest ordinary food. This may improve the quality of life of patients with gynecological cancer and help them recover more quickly from surgery.

Description:

PRIMARY OBJECTIVES: I. To compare the time-to-quality of life (QOL) improvement from baseline in postoperative gynecological cancer patients who are receiving oral serum bovine immunoglobulin (SBI) vs. placebo. SECONDARY OBJECTIVES: I. To compare the surgical complication rates between oral SBI vs. placebo up to 1 month post-surgery (safety endpoint). II. To compare the QOL, as derived from the previously-validated Symptom Distress Scale, the Postoperative Quality of Life questionnaire (PQL), and the uniscale (overall QOL item) between patients receiving oral SBI vs. placebo. III. To compare the grade 2 or worse adverse event rates for patients receiving oral SBI vs. placebo. IV. To characterize the adverse event profile of oral SBI in postoperative gynecological cancer patients (safety endpoint). V. To compare supplement adherence between patients receiving oral SBI vs. placebo. TERTIARY OBJECTIVES: I. To explore whether candidate biomarkers are modified with SBI versus placebo. II. As part of ongoing research, to bank leftover blood samples for future studies. III. To explore quality of life during postoperative recovery after gynecologic surgery, regardless of whether or not patients take the study intervention/placebo or discontinue intervention/placebo early. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive SBI orally (PO) twice daily (BID) on days 1-28. ARM II: Patients receive placebo PO BID on days 1-28. In both arms, treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 4 weeks.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 58
• Est. completion date: October 2024
• Est. primary completion date: November 21, 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of gynecological cancer of any type or strong suspicion for cancer
• Patients must have begun postoperative oral intake of food prior to registration
• Open laparotomy or laparoscopic surgery undertaken with cancer therapeutic intent (not a subsequent surgery to manage a postoperative complication) that had occurred =< 7 days prior to registration and that entailed more than a simple hysterectomy
• Creatinine =< 1.5 x the upper limit of normal (ULN)
• Absolute neutrophil count >= 1500/mm^3
• Platelet count >= 100,000/mm^3
• Ability to complete questionnaire(s) by themselves or with assistance
• Provide informed written consent
• Negative (serum) pregnancy test done =< 7 days prior to randomization, for women of childbearing potential only
• Willing to provide mandatory baseline blood samples for correlative research purposes

Exclusion Criteria:

• Symptomatic and/or untreated brain metastases
• Ongoing parenteral nutrition (receiving intravenous nutrition support at the time of enrollment); note: patients may be receiving maintenance intravenous (IV) fluids
• Current enrollment in any other trial that entails the concurrent administration of any other agent designed to enhance postoperative recovery
• Allergy to beef

Related Conditions & MeSH terms

• Female Reproductive Cancer

Intervention

Biological:
• serum-derived bovine immunoglobulin protein isolate
Given PO

Other:
• placebo
Given PO
• laboratory biomarker analysis
Correlative studies
• quality-of-life assessment
Ancillary studies
• questionnaire administration
Ancillary studies

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time-to-QOL Improvement Defined as Any Increase in the QOL Score Measured Using the Total Score of the 14-item Postoperative Quality of Life (PQL) Tool	For this endpoint, the total QOL score could range from 1 to 140 (0 being the worst and 140 being the best). The primary analysis will be a comparison of oral SBI vs. placebo using a two-sided log-rank test between the 2 Kaplan-Meier curves.the total score of the 14-item Postoperative Quality of Life (PQL) tool [15] will be used, where the total score could range from 0 to 140 (0 being the worst and 140 being the best). These scores will be converted to the percentage scale, where a score of 140 will be converted to 100 and a score of 0 will remain as 0. This QOL will be measured weekly for the entire 12 week length of the study and at the end of the intervention. QOL improvement will be defined as at least a 10 point increase in the QOL score from baseline, on the percentage scale.	up to 25 months
Secondary	Overall Adverse Event Rates for Grade 2 or Higher Adverse Events, Graded According to the Common Terminology Criteria for Adverse Events Version 4.0	Frequency tables will be reviewed to determine adverse event patterns, this data is reported in the adverse events section of this report. Below is the number of patients that experienced an adverse event greater than or equal to 2.	up to 25 months
Secondary	Surgical Complication Rates	Compared between the 2 arms using Chi-Square or Fisher's Exact tests.	Up to 1 month post-surgery
Secondary	Intervention Compliance Assessed Using the Compliance Questionnaire	The frequency and percentage for each Compliance Questionnaire category will be summarized descriptively by cycle and by intervention arm. In addition, cycle by cycle compliance data will be compared between the 2 arms using a Chi-square test.	up to 25 months
Secondary	Change in QOL Measured Using the 14-item PQL Tool, Uniscale, and the Previously-validated Symptom Distress Scale	All 14 of the individual items from the PQL tool, along with the 4 additional items after the PQL questions will be analyzed and compared between the 2 intervention arms. Differences between post-randomization and baseline QOL scores will be analyzed and compared between the 2 arms using a Wilcoxon Rank-sum test. Also, other graphical and statistical methods will be used to compare the QOL between the 2 arms over time. For this endpoint, the total QOL score could range from 1 to 140 (0 being the worst and 140 being the best). These scores will be converted to the percentage scale, where a score of 140 will be converted to 100 and a score of 0 will remain as 0. This QOL will be measured weekly for the entire 12 week length of the study and at the end of the intervention. QOL improvement will be defined as at least a 10 point increase in the QOL score from baseline, on the percentage scale.	up to 25 months
Secondary	Change in QOL in Patients Who do Not Start Intervention or Discontinue Early, Measured Using the 14-item PQL Tool, Uniscale, and the Previously-validated Symptom Distress Scale	Analysis will be descriptive in nature to see if these patients have a poorer QOL than patients who stay on study.	Baseline up to 25 months